Tuesday's ETF Winners & Losers

Foreign-market-related funds rise with a rebound in overseas markets.
Author:
Publish date:

Foreign-market-related exchange-traded funds were among the best ETF performers Tuesday as overseas bourses bounced after several losing sessions.

Tokyo's Nikkei rose 1.2%, Hong Kong's Hang Seng added 2.1%, and China's Shanghai and Shenzhen 300 climbed nearly 2%. European markets were also rising.

The

iShares MSCI Malaysia Index

(EWM) - Get Report

ETF was climbing 5.7% to $9.51. The

iShares FTSE/Xinhua China 25 Index

(FXI) - Get Report

was recently up 4% to $95.31. The

Vanguard Emerging Markets Stock

(VWO) - Get Report

ETF was rising 3.2% to $73.37. The

iShares MSCI Emerging Markets Index

(EEM) - Get Report

was higher by 3.1% to $108.59.

ETFs tracking metals and mining were also rebounding Tuesday. Gold was recently higher by $4.90 to $644.10 an ounce, and silver was tacking on 13.5 cents to $12.88 an ounce.

The

Market Vectors Gold Miners

(GDX) - Get Report

ETF was gaining 2.6% to $37.87. The

SPDR S&P Metals & Mining

(XME) - Get Report

ETF was adding 2.3% to $52.01. The

iShares Silver Trust

(SLV) - Get Report

was higher by 2.2% to $128.25.

Semiconductor-related ETFs were also higher. Among individual stock names,

Taiwan Semiconductor

(TSM) - Get Report

was rising 4.4%,

Broadcom

(BRCM)

was adding 2.6%,

Xilinx

(XLNX) - Get Report

was higher by 2%, and

Texas Instruments

(TXN) - Get Report

was recently up 1.7%.

Those chip ETFs getting a lift were the

PowerShares Dynamic Semiconductors

(PSI) - Get Report

, which was rising 2.1% to $17.79; the

iShares Goldman Sachs Semiconductor

(IGW)

, up 1.9% to $60.71; the

SPDR Semiconductor

(XSD) - Get Report

ETF, adding 1.8% to $49.74; and the

Semiconductors HOLDRs

(SMH) - Get Report

ETF, which was higher by 1.4% to $33.83.

The

First Trust Amex Biotech Index

(FBT) - Get Report

was one of the session's few losers. Holding

InterMune

(ITMN)

was dropping more than 20% after the company said late Monday that a phase III clinical trial for its Actimmune pulmonary drug showed poor results. The ETF was lower by 7 cents, or 0.3%, to $22.12.